BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

270 related articles for article (PubMed ID: 23887294)

  • 21. Intraductal papillary mucinous neoplasms of the pancreas with distinct pancreatic ductal adenocarcinomas are frequently of gastric subtype.
    Ideno N; Ohtsuka T; Kono H; Fujiwara K; Oda Y; Aishima S; Ito T; Ishigami K; Tokunaga S; Ohuchida K; Takahata S; Nakamura M; Mizumoto K; Tanaka M
    Ann Surg; 2013 Jul; 258(1):141-51. PubMed ID: 23532108
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The clinicopathological significance of ALK rearrangements and KRAS and EGFR mutations in primary pulmonary mucinous adenocarcinoma.
    Qu Y; Che N; Zhao D; Zhang C; Su D; Zhou L; Zhang L; Wang C; Zhang H; Wei L
    Tumour Biol; 2015 Aug; 36(8):6417-24. PubMed ID: 25813151
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Integration of KRAS testing in the diagnosis of pancreatic cystic lesions: a clinical experience of 618 pancreatic cysts.
    Nikiforova MN; Khalid A; Fasanella KE; McGrath KM; Brand RE; Chennat JS; Slivka A; Zeh HJ; Zureikat AH; Krasinskas AM; Ohori NP; Schoedel KE; Navina S; Mantha GS; Pai RK; Singhi AD
    Mod Pathol; 2013 Nov; 26(11):1478-87. PubMed ID: 23743931
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Associations between mutations and histologic patterns of mucin in lung adenocarcinoma: invasive mucinous pattern and extracellular mucin are associated with KRAS mutation.
    Kadota K; Yeh YC; D'Angelo SP; Moreira AL; Kuk D; Sima CS; Riely GJ; Arcila ME; Kris MG; Rusch VW; Adusumilli PS; Travis WD
    Am J Surg Pathol; 2014 Aug; 38(8):1118-27. PubMed ID: 25029118
    [TBL] [Abstract][Full Text] [Related]  

  • 25. CDX-2 Expression in Primary Lung Adenocarcinoma.
    Cowan ML; Li QK; Illei PB
    Appl Immunohistochem Mol Morphol; 2016 Jan; 24(1):16-9. PubMed ID: 26469326
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Identification of EGFR mutation, KRAS mutation, and ALK gene rearrangement in cytological specimens of primary and metastatic lung adenocarcinoma.
    Cai G; Wong R; Chhieng D; Levy GH; Gettinger SN; Herbst RS; Puchalski JT; Homer RJ; Hui P
    Cancer Cytopathol; 2013 Sep; 121(9):500-7. PubMed ID: 23495083
    [TBL] [Abstract][Full Text] [Related]  

  • 27. HNF4α as a marker for invasive mucinous adenocarcinoma of the lung.
    Sugano M; Nagasaka T; Sasaki E; Murakami Y; Hosoda W; Hida T; Mitsudomi T; Yatabe Y
    Am J Surg Pathol; 2013 Feb; 37(2):211-8. PubMed ID: 23108025
    [TBL] [Abstract][Full Text] [Related]  

  • 28. KRAS mutant allele-specific imbalance in lung adenocarcinoma.
    Chiosea SI; Sherer CK; Jelic T; Dacic S
    Mod Pathol; 2011 Dec; 24(12):1571-7. PubMed ID: 21743433
    [TBL] [Abstract][Full Text] [Related]  

  • 29. KRAS and NKX2-1 Mutations in Invasive Mucinous Adenocarcinoma of the Lung.
    Hwang DH; Sholl LM; Rojas-Rudilla V; Hall DL; Shivdasani P; Garcia EP; MacConaill LE; Vivero M; Hornick JL; Kuo FC; Lindeman NI; Dong F
    J Thorac Oncol; 2016 Apr; 11(4):496-503. PubMed ID: 26829311
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Comparison of EGFR and KRAS mutations in primary and unpaired metastatic lung adenocarcinoma with potential chemotherapy effect.
    Munfus-McCray D; Cui M; Zhang Z; Gabrielson E; Askin F; Li QK
    Hum Pathol; 2013 Jul; 44(7):1286-92. PubMed ID: 23337026
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Large duct type invasive adenocarcinoma of the pancreas with microcystic and papillary patterns: a potential microscopic mimic of non-invasive ductal neoplasia.
    Bagci P; Andea AA; Basturk O; Jang KT; Erbarut I; Adsay V
    Mod Pathol; 2012 Mar; 25(3):439-48. PubMed ID: 22056954
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cribriform adenocarcinoma of the lung: clinicopathologic, immunohistochemical, and molecular analysis of 15 cases of a distinctive morphologic subtype of lung adenocarcinoma.
    Mackinnon AC; Luevano A; de Araujo LC; Rao N; Le M; Suster S
    Mod Pathol; 2014 Aug; 27(8):1063-72. PubMed ID: 24390215
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Subtype-specific KRAS mutations in advanced lung adenocarcinoma: a retrospective study of patients treated with platinum-based chemotherapy.
    Cserepes M; Ostoros G; Lohinai Z; Raso E; Barbai T; Timar J; Rozsas A; Moldvay J; Kovalszky I; Fabian K; Gyulai M; Ghanim B; Laszlo V; Klikovits T; Hoda MA; Grusch M; Berger W; Klepetko W; Hegedus B; Dome B
    Eur J Cancer; 2014 Jul; 50(10):1819-1828. PubMed ID: 24768329
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The Kras mutational spectra of chemically induced lung tumors in different inbred mice mimics the spectra of KRAS mutations in adenocarcinomas in smokers versus nonsmokers.
    Fritz JM; Dwyer-Nield LD; Russell BM; Malkinson AM
    J Thorac Oncol; 2010 Feb; 5(2):254-7. PubMed ID: 20101149
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The prognostic and predictive value of KRAS oncogene substitutions in lung adenocarcinoma.
    Villaruz LC; Socinski MA; Cunningham DE; Chiosea SI; Burns TF; Siegfried JM; Dacic S
    Cancer; 2013 Jun; 119(12):2268-74. PubMed ID: 23526491
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A comparison of EGFR and KRAS status in primary lung carcinoma and matched metastases.
    Monaco SE; Nikiforova MN; Cieply K; Teot LA; Khalbuss WE; Dacic S
    Hum Pathol; 2010 Jan; 41(1):94-102. PubMed ID: 19740513
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Frequency of well-identified oncogenic driver mutations in lung adenocarcinoma of smokers varies with histological subtypes and graduated smoking dose.
    Li H; Pan Y; Li Y; Li C; Wang R; Hu H; Zhang Y; Ye T; Wang L; Shen L; Sun Y; Chen H
    Lung Cancer; 2013 Jan; 79(1):8-13. PubMed ID: 23098378
    [TBL] [Abstract][Full Text] [Related]  

  • 38. LEF-1 is frequently expressed in colorectal carcinoma and not in other gastrointestinal tract adenocarcinomas: an immunohistochemical survey of 602 gastrointestinal tract neoplasms.
    Kermanshahi TR; Jayachandran P; Chang DT; Pai R
    Appl Immunohistochem Mol Morphol; 2014; 22(10):728-34. PubMed ID: 25394300
    [TBL] [Abstract][Full Text] [Related]  

  • 39. EGFR fluorescence in situ hybridization-positive lung adenocarcinoma: incidence of coexisting KRAS and BRAF mutations.
    Chiosea S; Shuai Y; Cieply K; Nikiforova MN; Dacic S
    Hum Pathol; 2010 Aug; 41(8):1053-60. PubMed ID: 20381121
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Loss of heterozygosity predicts poor survival after resection of pancreatic adenocarcinoma.
    Franko J; Krasinskas AM; Nikiforova MN; Zarnescu NO; Lee KK; Hughes SJ; Bartlett DL; Zeh HJ; Moser AJ
    J Gastrointest Surg; 2008 Oct; 12(10):1664-72; discussion 1672-3. PubMed ID: 18677542
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.